These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24965460)

  • 1. Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes.
    Su B; Lederle A; Laumond G; Ducloy C; Schmidt S; Decoville T; Moog C
    J Virol; 2014 Sep; 88(18):10975-81. PubMed ID: 24965460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
    Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.
    Gombos RB; Kolodkin-Gal D; Eslamizar L; Owuor JO; Mazzola E; Gonzalez AM; Korioth-Schmitz B; Gelman RS; Montefiori DC; Haynes BF; Schmitz JE
    J Virol; 2015 Aug; 89(15):7813-28. PubMed ID: 25995259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short Communication: Exploring Antibody Potential as Prophylactic/Therapeutic Strategies for Prevention of Early Mucosal HIV-1 Infection.
    Su B; Peressin M; Ducloy C; Penichon J; Mayr LM; Laumond G; Schmidt S; Decoville T; Moog C
    AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1187-91. PubMed ID: 26252799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV transmission from infected CD4+ T cells to allogenic T and dendritic cells is inhibited by broadly neutralizing antibodies.
    Ducloy C; Su B; Mayr L; Klingler J; Decoville T; Schmidt S; Laumond G; Salomé N; Bahram S; Moog C
    AIDS; 2018 Jun; 32(10):1239-1245. PubMed ID: 29683853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibodies inhibit HIV-1 infection of plasmacytoid dendritic cells by an FcγRIIa independent mechanism and do not diminish cytokines production.
    Lederle A; Su B; Holl V; Penichon J; Schmidt S; Decoville T; Laumond G; Moog C
    Sci Rep; 2014 Aug; 4():5845. PubMed ID: 25132382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing antibodies inhibit HIV-1 transfer from primary dendritic cells to autologous CD4 T lymphocytes.
    Su B; Xu K; Lederle A; Peressin M; Biedma ME; Laumond G; Schmidt S; Decoville T; Proust A; Lambotin M; Holl V; Moog C
    Blood; 2012 Nov; 120(18):3708-17. PubMed ID: 22955927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.
    Lynch RM; Wong P; Tran L; O'Dell S; Nason MC; Li Y; Wu X; Mascola JR
    J Virol; 2015 Apr; 89(8):4201-13. PubMed ID: 25631091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials.
    Huang Y; Naidoo L; Zhang L; Carpp LN; Rudnicki E; Randhawa A; Gonzales P; McDermott A; Ledgerwood J; Lorenzo MMG; Burns D; DeCamp A; Juraska M; Mascola J; Edupuganti S; Mgodi N; Cohen M; Corey L; Andrew P; Karuna S; Gilbert PB; Mngadi K; Lazarus E
    EBioMedicine; 2021 Feb; 64():103203. PubMed ID: 33493795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor.
    Kong L; Ju B; Chen Y; He L; Ren L; Liu J; Hong K; Su B; Wang Z; Ozorowski G; Ji X; Hua Y; Chen Y; Deller MC; Hao Y; Feng Y; Garces F; Wilson R; Dai K; O'Dell S; McKee K; Mascola JR; Ward AB; Wyatt RT; Li Y; Wilson IA; Zhu J; Shao Y
    Immunity; 2016 Apr; 44(4):939-50. PubMed ID: 27067056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
    Wu X; Wang C; O'Dell S; Li Y; Keele BF; Yang Z; Imamichi H; Doria-Rose N; Hoxie JA; Connors M; Shaw GM; Wyatt RT; Mascola JR
    J Virol; 2012 May; 86(10):5844-56. PubMed ID: 22419808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice.
    Sun M; Li Y; Yuan Z; Lu W; Kang G; Fan W; Li Q
    Arch Virol; 2016 Sep; 161(9):2449-55. PubMed ID: 27343044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells.
    Frankel SS; Steinman RM; Michael NL; Kim SR; Bhardwaj N; Pope M; Louder MK; Ehrenberg PK; Parren PW; Burton DR; Katinger H; VanCott TC; Robb ML; Birx DL; Mascola JR
    J Virol; 1998 Dec; 72(12):9788-94. PubMed ID: 9811714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follicular dendritic cells and human immunodeficiency virus infectivity.
    Heath SL; Tew JG; Tew JG; Szakal AK; Burton GF
    Nature; 1995 Oct; 377(6551):740-4. PubMed ID: 7477265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.
    Lynch RM; Boritz E; Coates EE; DeZure A; Madden P; Costner P; Enama ME; Plummer S; Holman L; Hendel CS; Gordon I; Casazza J; Conan-Cibotti M; Migueles SA; Tressler R; Bailer RT; McDermott A; Narpala S; O'Dell S; Wolf G; Lifson JD; Freemire BA; Gorelick RJ; Pandey JP; Mohan S; Chomont N; Fromentin R; Chun TW; Fauci AS; Schwartz RM; Koup RA; Douek DC; Hu Z; Capparelli E; Graham BS; Mascola JR; Ledgerwood JE;
    Sci Transl Med; 2015 Dec; 7(319):319ra206. PubMed ID: 26702094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro inhibition of HIV-1 replication in autologous CD4
    Tu T; Zhan J; Mou D; Li W; Su B; Zhang T; Li T; Li N; Wu H; Jin C; Chen H
    Virol Sin; 2017 Dec; 32(6):485-494. PubMed ID: 28918477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission.
    Malbec M; Porrot F; Rua R; Horwitz J; Klein F; Halper-Stromberg A; Scheid JF; Eden C; Mouquet H; Nussenzweig MC; Schwartz O
    J Exp Med; 2013 Dec; 210(13):2813-21. PubMed ID: 24277152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides.
    Hamorsky KT; Grooms-Williams TW; Husk AS; Bennett LJ; Palmer KE; Matoba N
    Antimicrob Agents Chemother; 2013 May; 57(5):2076-86. PubMed ID: 23403432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.